| |
MEDIA INQUIRIES
Mike Beyer
Sam Brown Inc.
Phone:
773-463-4211
beyer@sambrown.com
|
|
August 11, 2011
Yaupon Therapeutics, Inc. Secures $14.4
Million in Series D Financing
MALVERN, PA (August 11, 2011) –
Yaupon Therapeutics, Inc., a privately held
specialty pharmaceutical company, announced today that it has
raised $14.4 million through a Series D private placement of
preferred stock. The new round includes prior investors Vivo
Ventures, Palo Alto Investors and Burrill & Company, plus new
investor, Aperture Venture Partners.
Yaupon recently submitted a New Drug
Application (NDA) to the FDA for a proprietary gel formulation
of mechlorethamine hydrochloride for the treatment of early
stage (stages I-IIA) mycosis fungoides, the most common type of
cutaneous T-cell lymphoma (CTCL).
“This financing provides us with the necessary
capital to take us through the NDA regulatory review process,
while preparing for commercialization either alone or with an
industry partner,” said Yaupon Chairman and CEO Steve Tullman.
“We appreciate the strong support of existing and new investors
and their ongoing confidence in the potential of our product for
the treatment of this common type of CTCL.”
About Yaupon Therapeutics
Yaupon Therapeutics, a privately held, specialty pharmaceutical company, is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of cutaneous T-cell lymphoma (CTCL). If approved, Yaupon’s investigational drug would be the first topical mechlorethamine gel widely available to treat the signs and symptoms of this rare cancer. Please visit the new Yaupon website
www.yaupontherapeutics.com for more information.
# # #
|
|
